Securities code: 688029 Securities abbreviation: South Micro Medical Announcement No.: 2023-009.

Nanwei Medical Technology Co., Ltd.

2022 Annual Performance Express Announcement

the company's board of directors and all directors to ensure that the contents of this announcement does not exist any false records, misleading statements or major omissions, and the authenticity, accuracy and completeness of the contents of the legal responsibility.

The main financial data of Nanwei Medical Technology Co., Ltd. (hereinafter referred to as the "Company") in 2022 contained in this announcement are preliminary accounting data, which have not been audited by an accounting firm. The specific data are subject to the data disclosed in the company's 2022 annual report. Investors are reminded to pay attention to investment risks.

Key Financial Data and Indicators for 1. 2022

Unit: RMB ten thousand yuan

Changes in the same period of the previous year (%)

Total operating income 198,025.80 194,672.40 1.72

Operating profit 36,248.65 36,718.48 -1.28

Total profit 36,619.66 37,734.48 -2.95

Net profit attributable to owners of the parent company 32,863.00 32,475.05 1.19

Deductions attributable to owners of the parent non -29,656.76 27,562.27 7.60

Net profit from recurring gains and losses

Basic earnings per share (RMB) 1.7551 1.7396 0.89

Weighted average ROE 10.75 per cent 11.81 per cent down 1.06 percentage points

Increase or decrease at the end of the reporting period at the beginning of the reporting period (%)

Total assets 389,421.42 363,174.68 7.23

Owners' equity attributable to the parent company 322,332.48 294,332.20 9.51

Share capital 18,781.14 13,374.72 40.42

Net 17.16 22.01 per share attributable to owners of the parent -22.01

Assets (RMB)

Note: The beginning of the reporting period is the same as the statutory disclosure at the end of the previous year. The above financial data and indicators are presented in the consolidated financial statements, but have not been audited, and the final results are based on the Company's 2022 annual report.

Statement of 2. results of operations and financial position

Description of operations and financial position for the (I) reporting period.

In 2022, in the face of adverse environments such as repeated domestic new crown epidemics, rising foreign inflation rates, and increasing labor costs and transportation costs, the company will give full play to its long-term accumulated brand, quality and channel advantages, strengthen the introduction of new endoscopic products and the development of the non-public medical market, give full play to the company's development resilience, carry out all aspects of operation in an orderly manner, minimize the losses caused by epidemic containment, and maintain a steady and rising development trend.

In 2022, the company achieved total operating income of 1980.258 million yuan, an increase of 1.72 over the same period last year;

The net profit attributable to the owners of the parent company was 328.63 million yuan, an increase of 1.19 over the same period last year; the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses was 296.5676 million yuan, an increase of 7.60 over the same period last year.

At the end of the reporting period, the company's financial status was good, with total assets of 3,894.2142 million billion yuan, an increase of 7.23 over the beginning of the reporting period; the owner's equity attributable to the parent company was 3,223.3248 million yuan, an increase of 9.51 over the beginning of the reporting period.

Description of the indicator of a (II) change of more than 30 per cent

At the end of the reporting period, the total share capital of the company was 187.8114 million billion yuan, up 40.42 from the previous period, mainly due to the current period.

4 shares for every 10 shares of capital stock in 2021, and the 2020 restricted stock incentive plan.

The ownership of the shares results in an increase in the share capital.

3. Risk Alert

The main financial data for 2022 contained in this announcement are preliminary accounting data, which have not been audited by an accounting firm. The specific data are subject to the data disclosed in the company's 2022 annual report. Investors are requested to pay attention to investment risks.

It is hereby announced.

Board of Directors of South Micro Medical Technology Co., Ltd.

28 February 2023